eMedicine Specialties > Infectious Diseases > Skin and Soft-Tissue Infections
Diabetic Foot Infections
Updated: Aug 12, 2009
Introduction
Background
Foot infections are the most common problems in persons with diabetes. These individuals are predisposed to foot infections because of a compromised vascular supply secondary to diabetes. Local trauma and/or pressure (often in association with lack of sensation because of neuropathy), in addition to microvascular disease, may result in various diabetic foot infections. For additional information, see Medscape’s Diabetic Microvascular Complications Resource Center.
The spectrum of foot infections in diabetes ranges from simple superficial cellulitis to chronic osteomyelitis. Infections in patients with diabetes are difficult to treat because these patients have impaired microvascular circulation, which limits the access of phagocytic cells to the infected area and results in a poor concentration of antibiotics in the infected tissues. For this reason, cellulitis is the most easily treatable and reversible form of foot infections in patients with diabetes. Deep skin and soft tissue infections are also usually curable, but they can be life threatening and result in substantial long-term morbidity.
In terms of the infecting microorganisms and the likelihood of successful treatment with antimicrobial therapy, acute osteomyelitis in people with diabetes is essentially the same as in those without diabetes. Chronic osteomyelitis in patients with diabetes mellitus is the most difficult infection to cure. Adequate surgical debridement, in addition to antimicrobial therapy, is necessary to cure chronic osteomyelitis.
Patients with diabetes also can have a combined infection involving bone and soft tissue called fetid foot. This extensive, chronic soft tissue and bone infection causes a foul exudate and usually requires extensive surgical debridement and/or amputation.
Individuals with diabetes may also have peripheral vascular disease that involves the large vessels, in addition to microvascular and capillary disease that results in peripheral vascular disease with gangrene. Dry gangrene is usually managed with expectant care, and gross infection is usually not present. Wet gangrene usually has an infectious component and requires surgical debridement and/or antimicrobial therapy to control the infection.
Except for chronic osteomyelitis, infections in patients with diabetes are caused by the same microorganisms that can infect the extremities of those without diabetes. Gas gangrene is conspicuous because of its low incidence in patients with diabetes, but deep skin and soft tissue infections, which are due to gas-producing organisms, frequently occur in patients with diabetes. In general, people with diabetes have infections that are more severe and take longer to cure than equivalent infections in other people.
Pathophysiology
Diabetes mellitus is a disorder that primarily affects the microvascular circulation. In the extremities, microvascular disease due to "sugar-coated capillaries" limits the blood supply to the superficial and deep structures. Pressure due to ill-fitting shoes or trauma further compromises the local blood supply at the microvascular level, predisposing the patient to infection. The infection may involve the skin, soft tissues, bone, or all of these tissues.
Diabetes also accelerates macrovascular disease, which is evident clinically as accelerating atherosclerosis and/or peripheral vascular disease. Most diabetic foot infections occur in the setting of good dorsalis pedis pulses; this finding indicates that the primary problem in diabetic foot infections is microvascular compromise. Impaired microvascular circulation hinders white cell migration into the area of infection and limits the ability of antibiotics to reach the site of infection in an effective concentration. Diabetic neuropathy may be encountered in conjunction with vasculopathy. This may allow for incidental trauma that goes unrecognized (eg, blistering, penetrating foreign body).
In chronic osteomyelitis, a sequestrum and involucrum form; these represent islands of infected bone. Bone fragments that are isolated have no blood supply. Administered antibiotics do not penetrate the devascularized infected bone fragments; they can enter the area of osteomyelitis only via the remaining blood supply. Therefore, antibiotic therapy alone cannot cure patients with chronic osteomyelitis without surgical debridement to remove these isolated infected elements. Surgical debridement is essential to remove the infected bony fragments that the antibiotics cannot reach so that affected areas can be treated with antimicrobial therapy.
Frequency
International
Diabetic foot infections range from cellulitis to chronic osteomyelitis, and, globally, they are the most common skeletal and soft tissue infections in patients with diabetes.
Mortality/Morbidity
Mortality is not common, except in unusual circumstances. The mortality risk is highest in patients with chronic osteomyelitis and in those with acute necrotizing soft tissue infections.
Race
The incidence of diabetic foot infections is similar to that of diabetes in various ethnic groups.
Sex
No important sex differences exist.
Age
Diabetic foot infections most frequently affect elderly patients.
Clinical
History
Patients may or may not have a history of trauma or previous infection.
Physical
Findings after physical examination may include the following:
- Cellulitis
- Cellulitis may involve tender and erythematous nonraised skin lesions on the lower extremity that may or may not be accompanied by lymphangitis.
- Lymphangitis suggests a group A streptococcal etiology.
- If bullae are present, Staphylococcus aureus is the most likely pathogen, but group A streptococci occasionally causes bullous lesions.
- No ulcer or wound exudate is present in patients with cellulitis.
- Deep skin and soft tissue infections
- Patients with deep skin and soft tissue infections may be acutely ill, with painful induration of the soft tissues in the extremity.
- These infections are particularly common in the thigh area, but they may be seen anywhere on the leg or foot.
- Wound discharge is usually not present. In mixed infections that may involve anaerobes, crepitation may be noted over the afflicted area.
- Extreme pain and tenderness indicate the possibility of a compartment syndrome, which may be diagnosed with the aid of a CT scan. Similarly, extreme pain may be an indication of infection with clostridial species (ie, gas gangrene).
- The tissues are not tense, and bullae may be present.
- If a discharge is present, it is often foul.
- Acute osteomyelitis
- Unless peripheral neuropathy is present, the patient has pain at the site of the involved bone.
- Usually, fever and regional adenopathy are absent.
- Chronic osteomyelitis
- In chronic osteomyelitis, the patient's temperature is usually less than 102°F.
- Discharge is commonly foul.
- No lymphangitis is observed.
- Pain may or may not be present, depending on the degree of peripheral neuropathy.
- The deep penetrating ulcers and sinuses are usually located between the toes or on the plantar surface of the foot.
- In patients with diabetes, chronic osteomyelitis usually does not occur on the medial malleoli, shins, or heels.
- Importantly, deep penetrating foot ulcers or deep sinus tracts are diagnostic of chronic osteomyelitis.
Causes
The microbiologic features of diabetic foot infections vary according to the tissue infected.
- In patients with diabetes, superficial skin infections such as cellulitis are caused by the same organisms as those in healthy hosts, namely group A streptococci and S aureus. However, in unusual epidemiologic circumstances, organisms such as Pasteurella multocida (eg, from dog or cat bites or scratches) may be noted and should always be considered.
- Group B streptococcal cellulitis is uncommon in healthy hosts and not uncommon in patients with diabetes. In people with diabetes, group B streptococci may cause urinary tract infections and catheter-associated bacteriuria in addition to cellulitis, skin and/or soft tissue infections, and chronic osteomyelitis. Such infections may be complicated by bacteremia.
- In patients with diabetes, deep soft tissue infections can be associated with gas-producing gram-negative bacilli. Clinically, these infections appear as necrotizing fasciitis, compartment syndrome, or myositis. Gas gangrene is uncommon in persons with diabetes.
- Acute osteomyelitis usually occurs as a result of foot trauma in an individual with diabetes. The distribution of organisms is the same as in an individual without diabetes who has acute osteomyelitis.
- In chronic osteomyelitis, the pathogens are group A and group B streptococci, aerobic gram-negative bacilli, and Bacteroides fragilis, among others.
- Pseudomonas aeruginosa is generally not a pathogen in chronic osteomyelitis in patients with diabetes.
- P aeruginosa is frequently cultured from samples obtained from a draining sinus tract or deep penetrating ulcers in patients with diabetes. However, these organisms are superficial colonizers and are generally not the cause of the bone infection.
- Because Pseudomonas organisms are water-borne, superficial ulcers may be contaminated by bacteria in wet socks or dressings. To the author's knowledge, no well-documented cases of biopsy-proven P aeruginosa infection have been reported in patients with chronic osteomyelitis.
- Bone biopsy performed under aseptic conditions in the operating room reveals that chronic osteomyelitis in patients with diabetes is not due to P aeruginosa.
- B fragilis is an important bone pathogen in chronic osteomyelitis in patients with diabetes.
- Other pathogens implicated in chronic osteomyelitis in patients with diabetes include Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae.
- Fetid foot represents a combined deep skin and soft tissue infection caused by pathogens involved in chronic osteomyelitis.
More on Diabetic Foot Infections |
Overview: Diabetic Foot Infections |
| Differential Diagnoses & Workup: Diabetic Foot Infections |
| Treatment & Medication: Diabetic Foot Infections |
| Follow-up: Diabetic Foot Infections |
| Multimedia: Diabetic Foot Infections |
| References |
| Further Reading |
| Next Page » |
References
Malabu UH, Al-Rubeaan KA, Al-Derewish M. Diabetic foot osteomyelitis: usefulness of erythrocyte sedimentation rate in its diagnosis. West Afr J Med. Apr-Jun 2007;26(2):113-6. [Medline].
Andersen CA, Roukis TS. The diabetic foot. Surg Clin North Am. Oct 2007;87(5):1149-77, x. [Medline].
Armstrong DG, Lanthier J, Lelievre P, Edelson GW. Methicillin-resistant coagulase-negative staphylococcal osteomyelitis and its relationship to broad-spectrum oral antibiosis in a predominantly diabetic population. J Foot Ankle Surg. Nov-Dec 1995;34(6):563-6. [Medline].
Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care. May 1998;21(5):855-9. [Medline].
Bridges RM Jr, Deitch EA. Diabetic foot infections. Pathophysiology and treatment. Surg Clin North Am. Jun 1994;74(3):537-55. [Medline].
Caputo GM, Joshi N, Weitekamp MR. Foot infections in patients with diabetes. Am Fam Physician. Jul 1997;56(1):195-202. [Medline].
Cunha BA. Antibiotic Essentials. 7th Ed. Royal Oak, MI: Physicians Press; 2008.
Cunha BA. Antibiotic selection for diabetic foot infections: a review. J Foot Ankle Surg. Jul-Aug 2000;39(4):253-7. [Medline].
Cunha BA. Diabetic foot infections. Emerg Med. 1997;10:115-24.
Cunha BA. Skin and soft tissue infections in patients with diabetes mellitus. Infect Dis Pract. 1997;10:94-5.
Day MR, Armstrong DG. Factors associated with methicillin resistance in diabetic foot infections. J Foot Ankle Surg. Jul-Aug 1997;36(4):322-5; discussion 331. [Medline].
Diamantopoulos EJ, Haritos D, Yfandi G, Grigoriadou M, Margariti G, Paniara O, et al. Management and outcome of severe diabetic foot infections. Exp Clin Endocrinol Diabetes. 1998;106(4):346-52. [Medline].
Edelson GW, Armstrong DG, Lavery LA, Caicco G. The acutely infected diabetic foot is not adequately evaluated in an inpatient setting. J Am Podiatr Med Assoc. Jun 1997;87(6):260-5. [Medline].
Edmiston CE, Krepel CJ, Seabrook GR, Somberg LR, Nakeeb A, Cambria RA, et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother. Mar 2004;48(3):1012-6. [Medline].
Gleckman RA, Roth RM. Diabetic foot infections--prevention and treatment. West J Med. Feb 1985;142(2):263-5. [Medline].
Goldstein EJ, Citron DM, Nesbit CA. Diabetic foot infections. Bacteriology and activity of 10 oral antimicrobial agents against bacteria isolated from consecutive cases. Diabetes Care. Jun 1996;19(6):638-41. [Medline].
Grayson ML. Diabetic foot infections. Antimicrobial therapy. Infect Dis Clin North Am. Mar 1995;9(1):143-61. [Medline].
Grayson ML, Gibbons GW, Balogh K, Levin E, Karchmer AW. Probing to bone in infected pedal ulcers. A clinical sign of underlying osteomyelitis in diabetic patients. JAMA. Mar 1 1995;273(9):721-3. [Medline].
Koutkia P, Mylonakis E, Boyce J. Cellulitis: evaluation of possible predisposing factors in hospitalized patients. Diagn Microbiol Infect Dis. Aug 1999;34(4):325-7. [Medline].
Lipsky BA. Medical treatment of diabetic foot infections. Clin Infect Dis. Aug 1 2004;39 Suppl 2:S104-14. [Medline].
Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet. Nov 12 2005;366(9498):1695-703. [Medline].
[Guideline] Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis. Oct 1 2004;39(7):885-910. [Medline].
Lipsky BA, Giordano P, Choudhri S, Song J. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate. J Antimicrob Chemother. Aug 2007;60(2):370-6. [Medline].
Lipsky BA, Pecoraro RE, Larson SA, Hanley ME, Ahroni JH. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Arch Intern Med. Apr 1990;150(4):790-7. [Medline].
Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother. Feb 2005;55(2):240-5. [Medline].
Morales WJ, Dickey SS, Bornick P, Lim DV. Change in antibiotic resistance of group B streptococcus: impact on intrapartum management. Am J Obstet Gynecol. Aug 1999;181(2):310-4. [Medline].
Perencevich EN, Kaye KD, Strausbaugh LJ. Acceptable rates of treatment failure in osteomyelitis involving the diabetic foot: A survey of infectious diseases consultants. CID. 2004;38:476-482.
Rathur HM, Boulton AJ. The diabetic foot. Clin Dermatol. Jan-Feb 2007;25(1):109-20. [Medline].
Reiber GE. The epidemiology of diabetic foot problems. Diabet Med. 1996;13 Suppl 1:S6-11. [Medline].
Sapico FL, Canawati HN, Witte JL, Montgomerie JZ, Wagner FW Jr, Bessman AN. Quantitative aerobic and anaerobic bacteriology of infected diabetic feet. J Clin Microbiol. Sep 1980;12(3):413-20. [Medline].
Senneville E. Antimicrobial interventions for the management of diabetic foot infections. Expert Opin Pharmacother. Feb 2005;6(2):263-73. [Medline].
Stein GE, Schooley S, Peloquin CA, Missavage A, Havlichek DH. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J Antimicrob Chemother. Oct 2007;60(4):819-23. [Medline].
Tan JS. Foot Infections in Diabetic Patients. Curr Infect Dis Rep. Oct 2004;6(5):377-379. [Medline].
Tan PL, Teh J. MRI of the diabetic foot: differentiation of infection from neuropathic change. Br J Radiol. Nov 2007;80(959):939-48. [Medline].
Wang S, Cunha BA, Hamid NS, Amato BM, Feuerman M, Malone B. Metronidazole single versus multiple daily dosing in serious intraabdominal/pelvic and diabetic foot infections. J Chemother. Aug 2007;19(4):410-6. [Medline].
West NJ. Systemic antimicrobial treatment of foot infections in diabetic patients. Am J Health Syst Pharm. Jun 1 1995;52(11):1199-207; quiz 1239-40. [Medline].
Wheat LJ, Allen SD, Henry M, Kernek CB, Siders JA, Kuebler T, et al. Diabetic foot infections. Bacteriologic analysis. Arch Intern Med. Oct 1986;146(10):1935-40. [Medline].
Zgonis T, Roukis TS. A systematic approach to diabetic foot infections. Adv Ther. May-Jun 2005;22(3):244-62. [Medline].
Keywords
diabetic foot infections, diabetic foot infection, diabetes-related foot infection, diabetes foot infection, fetid foot, diabetes, diabetes mellitus, foot infections, cellulitis, osteomyelitis, microvascular disease, group A streptococci, group B streptococci, Streptococcus, Staphylococcus aureus, S aureus, staph infection, chronic osteomyelitis
Overview: Diabetic Foot Infections